- Home
- HXHX vs CANF Comparison
HXHX vs CANF Comparison
Compare HXHX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | CANF |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | China | Israel |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.0M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | HXHX | CANF |
|---|---|---|
| Price | $0.42 | $3.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 190.7K | ★ 1.6M |
| Earning Date | 05-20-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.17 |
| 52 Week High | $1.84 | $10.40 |
Technical Indicators
Market Signals| Indicator | HXHX | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 49.71 |
| Support Level | $0.34 | $3.18 |
| Resistance Level | $0.56 | $3.60 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.97 | 29.66 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.